The Federal Competition Commission (CFC) has announced that it is barring Nestle SA from buying Pfizer Inc’d infant formula arm in Mexico, citing competition concerns. The deal would have been made for $11.85 billion, as Nestle outbid Groupe Danone SA last April to buy the infant formula business. The CFC determined that the eventual 71 percent stake in the sector for stage one and two formula, and an 88 percent stake for stage three formula, would be too much of a dominant position for Nestle. The CFC used quantitative techniques to come to its conclusion.
Featured News
Meta Halts Commercial Terms Rollout After Publishers Raise Concerns in EU, UK
Oct 28, 2026 by
CPI
Nvidia’s $12.9 Billion Hugging Face Deal Draws Justice Department Questions
Oct 28, 2026 by
CPI
Rolls-Royce’s UltraFan Wins £2.5 Billion UK Framework Deal
Oct 28, 2026 by
CPI
Taiwan Blocks Grab’s $600 Million Foodpanda Deal, Citing Uber Ties
Oct 28, 2026 by
CPI
South Korea Expands Food Price-Fixing Probe to Four Major Instant Noodle Makers
Oct 28, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI